All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Join our
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce
Saturday, November 2, 2024
8:50-9:50 CET
This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
Older patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) have poor outcomes with standard salvage chemotherapy and stem cell transplantation.1 Additionally, older patients and/or patients with poor Eastern Cooperative Oncology Group Performance Status (ECOG PS) have limited treatment options. Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, is approved by the U.S. Food and Drug Administration (FDA) as a second-line treatment for patients with LBCL. A post-hoc analysis from the ZUMA-1 trial (NCT02348216) and a survival analysis from the ZUMA-7 trial (NCT03391466) demonstrated the effectiveness of axi-cel in patients aged ≥65 years with R/R LBCL.1
Below, we summarize results from an analysis comparing real-world outcomes of axi-cel vs chemoimmunotherapy (CIT) in patients with R/R LBCL after ≥2 lines of therapy, including patients aged ≥65 years and/or had an ECOG PS of 2, published by Lunning et al.1 in American Journal of Hematology.
Table 1. Patient characteristics*
Baseline characteristics, % (unless otherwise specified) |
Axi-cel (n = 1,146) |
CIT (n = 469) |
Median age, years (range) |
62.3 (19.6–86.2) |
55.4 (19.8–81.2) |
<65 years |
61 |
86 |
≥65 years |
39 |
14 |
≥70 years |
20 |
6 |
ECOG PS |
|
|
0–1 |
85 |
63 |
≥2 |
4 |
11 |
Unknown |
11 |
26 |
Prior lines of therapy |
|
|
2 |
34 |
96 |
≥3 |
66 |
4 |
Axi-cel, axicabtagene ciloleucel; CIT, chemoimmunotherapy; ECOG PS, Eastern Cooperative Oncology Group Performance Status. |
Figure 1. Response rate analysis showing A ORR and B CR rates in the axi-cel group vs CIT group*
Axi-cel, axicabtagene ciloleucel; CIT, chemoimmunotherapy; CR, complete response; ECOG PS, Eastern Cooperative Oncology Group performance status; ORR, overall response rate.
*Adapted from Lunning, et al.1
Key learnings |
|
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox